



A spin-off from Institut Pasteur

END-TO-END SOLUTIONS for the screening of SARS-CoV-2 (COVID-19)

BioSpeedia is a spin-off from Institut Pasteur, the premier non-profit foundation that was founded in 1887 and has since originated 10 Nobel Prizes.

Launched in 2011, the company specializes in rapid tests across various infectious diseases.

BioSpeedia Overview



BioSpeedia is a French company headquartered at the innovation campus at St Etienne and has privileged access to **CHU of St Etienne, GIMAP and Ecole des Mines** and has a license from the Institut Pasteur granting access to major reagents.



BioSpeedia provides **both Antigen and Antibody** rapid testing kits that are **fast, accurate and reliable**.



BioSpeedia can provide up to **5 million test kits per month for each test** through our existing manufacturing facilities.





end-to-end solutions
for COVID-19 screening

**Rapid tests for
COVID-19**



Antibody tests

**Why are antibody
tests important**



 BioSpeedia
A spin-off from Institut Pasteur

How to use the tests



Definition: This is an immunochromatographic assay designed for the qualitative detection of specific IgM and IgG antibodies against SARS-CoV-2, in human whole blood, serum or plasma. It is intended to be used by the professionals as a screening test and as an aid in the early diagnosis of SARS-CoV-2 infection.

Features


Platform	Immunochromatographic Assay
Format	Cassette
Detection	Specific IgM and IgG antibodies against SARS-CoV-2
Specimen	Whole blood, serum or plasma
Specimen volume	20 µl
Assay time	5-10 minutes
Shelf life	18 months

Clinical performance: COVID-19 Rapid IgG/IgM Test has been validated by 5 hospitals located in 3 European countries (Italy, France, Germany). A study of 640 patients shows a sensitivity of 92.2% and a specificity of 98.1%. Results below:

Results (IgM+IgG)	PCR Positive	PCR Negative	Total	Sensitivity (PPA, Positive Percent Agreement)	Specificity (NPA, Negative Percent Agreement)
Positive	392	4	396	92.2% (392/425)	98.1% (211/215)
Negative	33	211	244		
Total	425	215	640		


Procedures (Simplified Version)

1




Add 20 µL of whole blood, serum or plasma to the sample well. Make sure there is no air bubble.

2



Add 1 drop of buffer to the same sample well. Read result within 15 minutes.

Result Interpretation





Why use antibody testing?



Conduct epidemiological studies; plan for social distancing



Find good candidates for convalescent plasma therapy



Identify children with MIS



Reassess medication for immune compromised patients



Identify *first-in-line* candidates for vaccination



Identify high-risk patients among asymptomatic populations

Why antibody testing is important



In communities with lower prevalence (5 – 25%), infection risk is very high. **Antibody tests** allow governments and organizations to remain alert on that potential risk and adjust measures and resources to **prevent** significant **loss of lives and businesses**.



Around 25% (approx. 1.8 billion people) of the world's population has **underlying medical conditions** including old-age, obesity, severe cardiac, liver, lung, asthma, diabetes, kidney. Antibody tests allow **high-risk asymptomatic** patients to know if they've been previously infected by COVID-19 and whether their underlying conditions have been adversely impacted and/or if any change is required in their prescription medications.



Periodic anti-body testing allows organizations to address their exposure to COVID-19 and assess whether additional distancing measures should be taken.



END-TO-END SOLUTIONS for the screening of SARS-CoV-2 (COVID-19)



ORDERING INFORMATION



BioSpeedia Rapid Antibody Test



Cat. No	Product Description	Test Specimen	Product Format	Intended Use	Storage Temp	Packing Size
BSD_0501	COVID19SEROSpeed-IgM-IgG (with disposable dropper, alcohol swab, lancet)	Whole blood, serum or plasma	Cassette	Coronavirus disease	4-30°C	25 T/ Kit

